
Presenting Author: Dr. Gerard Criner
Abstract/Poster ID: 325
**DISCLOSURES**

Dr. Criner reports grants and personal fees from Galaxo Smith Kline, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Chiesi, grants and personal fees from Mereo, personal fees from Verona, grants and personal fees from Astra Zeneca, grants and personal fees from Pulmonx, grants and personal fees from Pneumrx, personal fees from BTG, grants and personal fees from Olympus, grants and personal fees from Broncus, personal fees from EOLO, personal fees from NGM, grants and personal fees from Lungpacer, grants from Alung, grants and personal fees from Nuvaira, grants and personal fees from ResMed, grants and personal fees from Respironics, grants from Fisher Paykel, grants and personal fees from Patara, grants from Galapgos, outside the submitted work.

A subset of authors are employees and shareholders of Corvus Pharmaceuticals. SW and RM are inventors on patents owned by Corvus Pharmaceuticals related to this work.

There will be discussion about the use of products for non-FDA approved indications in this presentation.
CPI-006 IS AN ANTI-CD73 WITH IMMUNOMODULATORY PROPERTIES

- CD73 is an ectoenzyme present on subsets of B cells (70%) and T cells (CD4 10%, CD8 50%)
  - Costimulatory on T cells\(^1\)
  - Activation of B cells\(^2\)
- CPI-006 is a humanized IgG1 Fcγ receptor deficient anti-CD73 with unique properties\(^2,3\)
  - Differentiation of B cells into plasmablasts and Ig secretion
  - Increases expression of CD69
  - Induces memory B cells
- Ph 1/2 cancer trial demonstrates lymphocyte activation and effects on trafficking\(^2,3\)

\(^1\) Resta & Thompson, Cell Signaling, 1997
\(^2\) Luke, ASCO Annual Meeting, 2019
\(^3\) Willingham et al, medRxiv, 2020
B CELL ACTIVATING CPI-006 IMMUNOTHERAPY OF COVID-19

- Enhance anti-SARS-CoV-2 antibodies to improve clinical outcome
- Improve long term immunity and protection from re-infection
- Accelerate viral clearance/reduce the risk of spreading
- Foundational therapy for treatment or prevention of other infectious diseases
VACCINATION OF HUMANIZED MICE WITH CPI-006 AND SPIKE PROTEIN ELICITS ANTIGEN SPECIFIC IMMUNITY

- NSG-SGM3 mice vaccinated with CPI-006 + SARS-CoV-2 spike protein produce antigen specific antibodies
- Mice receiving spike protein + isotype control antibody do not mount a response.

Mice (n=4/group) were immunized with the recombinant SARS-CoV-2 spike protein in incomplete adjuvant on Day 1 and treated with CPI-006 or human IgG1 control for 15 days.
PHASE 1 COVID-19 TRIAL & PATIENT CHARACTERISTICS

Single dose (IV) escalation study in hospitalized patients with mild to moderate COVID-19
- Patients receive SoC; no patient received convalescent plasma or other antibody therapy
- No drug related adverse events or changes in quantitative serum immunoglobulins
- 95% of patients were from high-risk patient populations

<table>
<thead>
<tr>
<th>Cohort</th>
<th>Median Age Years (Range)</th>
<th>Median Days From POS to CPI-006 (Range)</th>
<th>Comorbidities</th>
<th>Median BMI in kg/m² (Range)</th>
<th>Median ALC k/mm³ (Range)</th>
<th>Median Time to Discharge (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort 4 (N=5) 5.0 mg/kg</td>
<td>56 (23-68)</td>
<td>5 (4-8)</td>
<td>DM, HTN, CKD, cancer</td>
<td>33.3 (23.3-47.5)</td>
<td>1.3 (0.7-2)</td>
<td>4.5* (3-8)</td>
</tr>
<tr>
<td>Cohort 3 (N=5) 3.0 mg/kg</td>
<td>53 (26-76)</td>
<td>5 (1-9)</td>
<td>DM, HTN, asthma, cancer</td>
<td>30.7 (26.5-33.9)</td>
<td>1.2 (1-2.2)</td>
<td>4 (2-23)</td>
</tr>
<tr>
<td>Cohort 2 (N=7) 1 mg/kg</td>
<td>63 (37-76)</td>
<td>7 (3-&gt;21)</td>
<td>DM, CAD, HTN, COPD</td>
<td>33.2 (16.5-35.1)</td>
<td>0.9 (0.6-2.3)</td>
<td>4 (2-12)</td>
</tr>
<tr>
<td>Cohort 1 (N=5) 0.3 mg/kg</td>
<td>48 (28-72)</td>
<td>4 (1-8)</td>
<td>DM, CAD, HTN asthma, cancer</td>
<td>30.3 (24.6-33.7)</td>
<td>1.3 (0.8-1.5)</td>
<td>3 (3-4)</td>
</tr>
<tr>
<td>OVERALL (N=22)</td>
<td>58.5 (23-76)</td>
<td>5 (1-&gt;21)</td>
<td></td>
<td>32.2 (16.5-47.5)</td>
<td>1.1 (0.6-2.3)</td>
<td>4* (2-23)</td>
</tr>
</tbody>
</table>

* One patient is still hospitalized
SoC=Standard of Care, DM=diabetes, CAD=coronary artery disease, COPD=chronic lung disease, CKD=chronic kidney disease, HTN=hypertension
MAGNITUDE AND DURATION OF Anti-SARS-CoV2 RESPONSES

Dose-response with sustained titers

Ig responses to Spike and receptor binding domain (RBD) increase out to 28 days and high titers are sustained for 84+ days.

High IgM titers out to 84+ days.

Dose response observed, with higher and more prolonged titers at ≥1.0 mg/kg.

Neutralizing antibodies measured in pseudovirus assay out to 56+ days.

Ig responses to Spike and receptor binding domain (RBD) increase out to 28 days and high titers are sustained for 84+ days.

High IgM titers out to 84+ days.

Dose response observed, with higher and more prolonged titers at ≥1.0 mg/kg.

Neutralizing antibodies measured in pseudovirus assay out to 56+ days.

SITC2020 Poster 325
ANTIBODY TITERS REMAIN ELEVATED 84+ DAYS AFTER SYMPTOM ONSET

CPI-006 treated patients (left) compared to 343 hospitalized patients (right)\(^1\)

Sustained production of virus-specific IgG is associated with short disease duration\(^2\)

\(^1\)Iyer et al, Sci Trans Med, 2020
\(^2\)Chen et al, Cell, 2020
ANTI-VIRAL ANTIBODY RESPONSES ARE POLYCLONAL & POLYSPECIFIC

Serum antibody binding to N-terminal domain (NTD), receptor binding domain (RBD) or the S1 and S2 Spike subunits

Broad spectrum IgG activity to all subdomains, with IgM antibodies preferentially reacting with the RBD
INCREASED MEMORY & ANTIGEN SPECIFIC CELL RESPONSES

Increased frequency of peripheral memory B and memory/effector T cells measured by flow cytometry:
- Memory B cells: CD19\textsuperscript{POS}IgD\textsuperscript{NEG}CD27\textsuperscript{POS}
- Memory/effector T cells: CD3\textsuperscript{POS}CD45RA\textsuperscript{NEG}

PBMCs from patients treated with CPI-006 secrete IL-2 and IFN\gamma in response to SARS-CoV-2 membrane, nucleocapsid, and spike proteins.
CONCLUSIONS

- CPI-006 activates B cells, leading to lymphocyte trafficking, plasmablast differentiation, and antigen specific antibody secretion.
- Humanized mice vaccinated with CPI-006 and SARS-CoV-2 spike protein produce antigen specific antibodies.
- Single doses of 0.3 mg/kg - 5 mg/kg CPI-006 are well tolerated in hospitalized COVID-19 patients with no drug related adverse events.
- Dose dependent increases occur in the titers of IgG, IgM to SARS-CoV-2 spike and receptor binding domain.
- IgG and IgM titers to SARS-CoV-2 are sustained over 84+ days beyond onset of symptoms.
- Mapping studies show CPI-006 potentiates polyclonal antibody responses in COVID-19 patients targeting multiple epitopes within the N terminus, RBD, S1, S2 of SARS-CoV-2.
- Increased peripheral memory B cell and memory/effector T cell populations were observed. T cells release IFNγ and IL-2 consistent with antigen specific Th1 immune response.
- CPI-006 may by a foundation for therapy of other infectious diseases. A randomized controlled phase 3 study in COVID-19 is planned.
ACKNOWLEDGMENTS & ADDITIONAL INFORMATION

We thank the patients, their families, and the physicians, nurses, and staff at Temple University Hospital, El Centro, and Mt Sinai for their participation in these clinical studies.

Additional preclinical, translational, and clinical details provided in medRxiv paper

Characterization and Phase I Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19


doi: https://doi.org/10.1101/2020.09.10.20191486